Overview of Urimax-F

Property	Description
Active Ingredients	Tamsulosin Hydrochloride, Finasteride
Form	Modified Release Capsule (Oral)
Pharmacological Class	Alpha-blocker; 5-alpha reductase inhibitor
Common Use	Addressing enlarged prostate gland issues in men
Origin	Synthetic

What Type of Combination Medication is Urimax-F?

Urimax-F is a fixed-dose combination medication intended for oral administration in adult men, recognized for its dual pharmacological function as an alpha-blocker and a 5-alpha reductase inhibitor. This classification is clinically recognized globally, confirming the integrated action of its components. The product utilizes two distinct synthetic compounds to provide an integrated therapeutic action, strategically combining two drug classes into one unit. Fixed-dose combinations can simplify complex treatment plans, which is beneficial for patient adherence.

Composition of Urimax-F: Active Ingredients and Form

The product's composition is defined by its two active ingredients: Tamsulosin Hydrochloride and Finasteride. Tamsulosin Hydrochloride is classified as an alpha1-adrenergic receptor antagonist, and Finasteride is classified as a 5-alpha reductase inhibitor. Urimax-F is supplied as a Modified Release Capsule, an oral dosage form that is specifically engineered to control the absorption of the active substances over time. This controlled-release formulation allows for sustained delivery that is essential for maximizing the therapeutic window and patient convenience.

General Purpose and Dual Mechanism of Urimax-F

The general purpose of Urimax-F is to simultaneously reduce the physical size of the prostate tissue and provide relief from functional symptoms in the lower urinary tract. This objective is achieved through a dual mechanism that integrates two effects: the alpha-blocker component facilitates the relaxation of prostate muscles to immediately ease urinary flow, while the 5-alpha reductase inhibitor component works over time to help achieve the reduction of prostate size by targeting the mechanism responsible for tissue growth. Combination therapies such as this are often utilized to simultaneously manage symptoms and modify the underlying condition. This strategy is designed to address both the immediate functional difficulty and the underlying cause of the enlargement.

Regulatory References

What side effects are possible with Urimax-F?

Possible side effects and safety information

The official safety profile for the Tamsulosin and Finasteride fixed-dose combination, as documented in government regulatory sources, defines potential adverse reactions by frequency and physiological system.

Adverse Reaction Classification

Common adverse reactions—those occurring in ge 1% of patients in clinical studies—primarily include effects on the sexual and nervous systems. These frequently documented events are ejaculation disorders, decreased libido, impotence, dizziness, and headache. The reactions are categorized across System-Organ Classes including Reproductive System and Breast Disorders and Nervous System Disorders.

Serious Adverse Reactions that are formally noted in regulatory labeling include the rare but clinically significant event of Priapism (a persistent, painful erection) and severe allergic reactions such as Angioedema (swelling of the face or throat). Additionally, the use of 5-alpha reductase inhibitors is associated with a documented risk of high-grade prostate cancer.

Safety Considerations and Constraints

Safety notes specify that Orthostatic effects (a drop in blood pressure upon standing) are documented as being most common during the initiation of therapy. A specific constraint exists regarding the drug’s potential effect during surgery, as Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients exposed to the alpha-blocker component.

Furthermore, the Finasteride component significantly reduces serum Prostate-Specific Antigen (PSA) levels, a constraint that must be accounted for when interpreting diagnostic results. Official safety information also includes a warning that pregnant females must not handle crushed or broken capsules due to the potential risk to a male fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Urimax-F primarily presents clinical features related to the Tamsulosin component, an alpha-blocker, which requires immediate medical attention as mandated by official regulatory documents.

Overdose Manifestations	Required Emergency Actions
Severe Hypotension (profound low blood pressure) and reflex Tachycardia (rapid heart rate).	Seek immediate medical attention and contact emergency services or a Poison Control Center.
Potential for Cardiovascular Collapse is documented in severe cases of acute overexposure.	Hospital monitoring of vital signs and blood pressure is required until stable.
The Finasteride component is associated with no specific clinical manifestations listed at high doses.	Treatment is symptomatic and supportive.

Management and Regulatory Statements

The primary concern in an overdose scenario is the management of low blood pressure. Regulatory advice dictates placing the individual in a supine position to help restore circulation. If the hypotension persists and is severe, the official prescribing information states that the use of vasopressors may be necessary. Furthermore, measures such as the administration of activated charcoal or gastric lavage may be considered if the ingestion was recent. It is explicitly documented that no specific antidote is known for overdosage with this combination product, confirming the need for close observation and supportive care until the patient is stabilized.

Therapeutic Uses of Urimax-F

What Urimax-F treats: main uses and benefits

Urimax-F is a combination medication primarily used to manage symptoms associated with benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate gland. By combining two different therapeutic mechanisms, the medication addresses both the physical size of the prostate and the muscular tension within the urinary tract.

Main Uses

The primary application of this medication is the long-term treatment of symptomatic BPH in men. It is used to alleviate lower urinary tract symptoms (LUTS), which often manifest as:

Difficulty initiating urination: A delay or strain when starting to void.
Weak urinary stream: A flow that is slow or frequently interrupted.
Incomplete emptying: The sensation that the bladder is not fully empty after urination.
Urgency and frequency: A sudden, strong need to urinate or the need to urinate more often, including during the night.

Benefits and Mechanism of Action

Urimax-F provides clinical benefits by utilizing two active components that work in tandem to improve urinary flow and reduce the risk of condition progression.

Relaxation of Smooth Muscle

One component acts as an alpha-blocker, which targets the smooth muscles in the prostate and the bladder neck. By causing these muscles to relax, the medication reduces the functional obstruction of the urethra, allowing urine to pass more easily and providing relatively rapid relief from obstructive symptoms.

Reduction of Prostate Volume

The second component is a 5-alpha reductase inhibitor. This ingredient works by inhibiting the hormonal conversion responsible for prostate growth. Over time, this lead to a physical shrinking of the enlarged prostate gland. This dual approach not only manages current symptoms but also addresses the underlying cause of the enlargement.

Long-term Management

Beyond immediate symptom relief, the combination therapy is intended to improve the overall quality of life for individuals with BPH. By reducing the size of the prostate and improving urinary flow, the medication helps decrease the likelihood of acute urinary retention and may reduce the necessity for surgical intervention related to prostate enlargement.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

Adult men diagnosed with Benign Prostatic Hyperplasia (BPH).

Populations for whom use is contraindicated:

Women and pediatric patients (children and adolescents).
Women who are or may become pregnant.
Patients with documented hypersensitivity to Tamsulosin, Finasteride, or any excipients of the formulation.

Age-related eligibility rules:

Adult Men (18+): The single approved population.
Pediatric Patients: Use is contraindicated or not indicated as safety and efficacy are not established.

Condition-specific eligibility rules:

Patients with symptomatic orthostatic hypotension require caution due to the Tamsulosin component.
Caution is advised for patients with mild-to-moderate hepatic or renal impairment.
Use is generally not established in cases of severe hepatic impairment or end-stage renal disease.

Pregnancy and lactation eligibility status (if explicitly documented):

Pregnancy: Contraindicated in women.
Lactation: Not indicated for use in women.

Eligibility-related restrictions:

Pregnant women must not handle crushed or broken capsules.
Patients scheduled for cataract or glaucoma surgery must inform the surgeon of prior or current use.

Connection to the overall eligibility profile

Regulatory documents strictly limit the eligible user population to adult men due to the nature of the condition and the safety profile of the Finasteride component. Formal contraindications prohibit use by all women, pregnant individuals, and children. The profile outlines conditional constraints for patients with pre-existing cardiovascular issues or organ function limitations, necessitating cautious use as defined in official labeling.

What should I know about interactions with other medicines?

The drug Urimax-F is a combination of Tamsulosin and Finasteride. Its interaction profile is determined by the properties of these two active components, as documented in official regulatory labeling.

Interactions with other medicines and products

The interaction profile for Urimax-F is structured around two main risks: potential hypotension and changes in systemic exposure due to metabolic interactions.

Drug Classes and Specific Interacting Medicines

Interacting Class/Medicine	Basis of Interaction	Constraint/Requirement
Other Alpha-adrenergic Blocking Agents	Pharmacodynamic synergy (additive hypotensive effect)	Concomitant use is not recommended due to the risk of severe hypotension.
PDE5 Inhibitors (e.g., Sildenafil, Tadalafil)	Pharmacodynamic synergy (potential additive hypotensive effect)	Use with caution; patients should be monitored for orthostatic hypotension.
Strong/Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin)	Pharmacokinetic (reduced clearance of Tamsulosin)	Leads to significantly increased exposure of Tamsulosin; close monitoring is required.
Strong CYP2D6 Inhibitors (e.g., Paroxetine)	Pharmacokinetic (reduced clearance of Tamsulosin)	Increased Tamsulosin exposure; monitoring is required.

Finasteride-Specific Considerations

The Finasteride component is metabolized by the CYP3A4 enzyme; however, regulatory documents generally indicate that a dose adjustment is not required when co-administered with CYP3A4 inhibitors. A crucial interaction-related restriction is that Finasteride can significantly reduce serum Prostate-Specific Antigen (PSA) levels, impacting the interpretation of PSA test results for prostate cancer screening. Healthcare providers must be informed of this effect.

The official interaction documentation requires careful management or avoidance of certain combinations to mitigate risks related to blood pressure and drug concentration.

Mechanism of Action

The dual mechanism of action targets two distinct biological processes—muscle tone and glandular tissue growth—resulting in specific physiological changes.

1. Targeted Muscle Relaxation via Receptor Blockade

This domain describes the immediate action of the drug on alpha1A-adrenoceptors located on the smooth muscles of the bladder neck and prostate. By selectively blocking these receptors, the medication interrupts the nerve signal that causes tissue contraction, resulting in a physiological lowering of muscle tension. This action lowers the mechanical force exerted against the passage lumen, contributing to changes in the mechanical forces at the bladder outlet.

2. Regulation of Hormone-Driven Tissue Growth

This second domain involves the long-term, biochemical action of inhibiting the enzyme 5-alpha reductase. This action blocks the conversion of testosterone into the androgen, dihydrotestosterone (DHT), which is an androgen that influences prostate cell proliferation. The reduction in DHT levels modulates cell turnover, resulting in an eventual decrease in prostate tissue mass over time.

Dosage and Administration Information

Official Administration Guidelines

The usage of Urimax-F is defined by specific instructions governing its administration, frequency, and duration. This fixed-dose combination product is designated for oral administration only, using a Modified Release Capsule.

Property	Instruction / Rule
Route of administration	Oral administration only.
Dosing schedule	One Modified Release Capsule once daily (Tamsulosin 0.4 mg / Finasteride 5 mg).
Timing in relation to meals	Must be administered approximately 30 minutes after the same meal each day to control absorption.
Preparation requirements	None; the capsule must be swallowed intact.
Age-group administration rules	No specific dose adjustment is required for older adults or patients with moderate to severe renal impairment.
Missed-dose rules	If administration is interrupted for several days, re-initiation of therapy should begin at the appropriate starting dose regimen.
Special procedural conditions	The capsule must not be crushed, chewed, or opened to preserve its sustained-release profile.

Procedural Context and Course Duration

The official protocol dictates a long-term treatment commitment. While the Tamsulosin component's functional effect occurs quickly, the Finasteride component requires a minimum of three to six months of continuous, daily administration to achieve its full intended effect on prostate volume. This continuous use structures the overall therapeutic course. Furthermore, the presence of the 5-alpha reductase inhibitor imposes a procedural constraint: patients are restricted from donating blood for six months following the last dose of the medicine.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily (q.d.)
Use-context constraints	Constrained by fixed timing relative to meals and the intact nature of the capsule.

Recent Clinical Evidence

Urimax-F: Recent Clinical Evidence

Urimax-F is a combination medication containing tamsulosin (an alpha-blocker) and dutasteride (a 5-alpha reductase inhibitor). It is studied for the management of moderate-to-severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men who have an enlarged prostate.

Combination Therapy Outcomes

Clinical trials have investigated whether combination therapy with tamsulosin and dutasteride offers greater benefit than either medication used alone. The 4-year results from the Combination of Avodart and Tamsulosin (CombAT) study, a key randomized trial, examined outcomes in men with BPH and prostatic enlargement. The study focused on composite endpoints, including time to first acute urinary retention (AUR) or BPH-related surgery, and clinical progression of BPH.

Risk of Progression: The combination treatment was observed to be superior to both tamsulosin and dutasteride monotherapy at reducing the risk of overall clinical progression of BPH over the four-year period.
Symptom Improvement: Combination therapy was associated with significantly greater symptom benefit compared to either monotherapy at the four-year mark.

Safety and Long-Term Data

The long-term safety profile of the combination treatment was generally consistent with the known profiles of the individual components. The most frequently reported adverse events in these long-term studies related to sexual function, including decreased libido, difficulty with erection, and abnormal ejaculation.

Research found that these drug-related adverse events tended to diminish over time. The CombAT study also observed an imbalance in the composite term of cardiac failure among the three study arms, necessitating further analysis of cardiovascular risk.

Frequently Asked Questions (FAQ)

Common questions about Urimax-F (FAQ)

Q: Is Urimax-F the same as Flomax or other BPH medicines?

Urimax-F is classified as a fixed-dose combination medication. This means it contains two distinct active ingredients, one of which is Tamsulosin, the component found in single-agent medicines like Flomax (an alpha-blocker).

Official product information describes the combination drug as having a dual mechanism, which distinguishes it from medicines that only contain Tamsulosin or only Finasteride.

Q: What is the difference between Urimax-F and just Urimax?

Urimax-F is officially defined as containing a combination of the alpha-blocker (Tamsulosin) and the 5alpha-reductase inhibitor (Finasteride). The drug known as 'Urimax' typically contains only the alpha-blocker component (Tamsulosin).

Therefore, the 'F' indicates the fixed inclusion of the second active ingredient, which works to influence prostate size over time.

Q: What should be done if a dose of Urimax-F is forgotten?

Official administration guidelines provide instruction for extended treatment interruptions, noting that therapy is described in the guidance as requiring re-initiation at the appropriate regimen.

For a single missed dose, regulatory information for the components generally indicates that the dose may be taken if remembered soon after the scheduled time, but is generally described as being skipped if it is almost time for the next dose.

Q: What kind of monitoring is typically required while taking Urimax-F?

Official information indicates that monitoring is required while using Urimax-F. This typically includes periodic tests for Prostate-Specific Antigen (PSA) levels, as the Finasteride component can cause a reduction in the test results.

Additionally, patients are monitored for symptoms related to low blood pressure, especially when the medicine is first started or when other interacting drugs are used.

Q: What happens if I stop taking Urimax-F suddenly?

Studies and official information indicate that the benefits achieved with Urimax-F are generally lost once the medicine is discontinued, meaning symptoms may gradually return.

The drug's components are typically not associated with withdrawal symptoms when discontinued.

Q: Can I drink alcohol while using Urimax-F?

Official labeling for the Tamsulosin component describes that using alcohol may increase certain common side effects.

Specifically, these can include dizziness or feelings of lightheadedness due to the alpha-blocker component's effect on blood pressure.

Q: Are there any vitamins or supplements that interact with Urimax-F?

Official medical sources have noted interactions between the components of Urimax-F and certain herbal remedies. Regulatory information indicates that herbal supplements like St John's wort may potentially reduce the intended effects of the Finasteride component.

Q: What types of food or drink should be avoided when taking Urimax-F?

Official administration instructions define that the capsule is to be administered approximately 30 minutes after the same meal each day to ensure consistent absorption.

While maintaining this consistent timing is important, official regulatory documents do not formally list any specific types of food or drink that must be avoided entirely.

Q: Is Urimax-F known to affect hair growth or loss?

The 5alpha-reductase inhibitor component, Finasteride, is a medicine that has been studied and approved for use in treating male pattern hair loss.

This secondary effect occurs because the medicine influences levels of the androgen dihydrotestosterone (DHT) in the body.

Q: Do studies suggest that Urimax-F's effects last after stopping the drug?

Official information suggests that the positive changes achieved with the medicine, such as improvement in urinary symptoms and reduction in prostate size, are generally dependent on continued use.

Once the treatment is discontinued, these benefits are expected to be lost.

Q: Is there a generic version of Urimax-F?

The combination of Tamsulosin and Finasteride is available from several different manufacturers under various brand names.

This availability confirms that regulatory bodies have approved generic versions of the fixed-dose combination drug.

Q: Does Urimax-F interact with blood thinners?

Official regulatory labeling for the Tamsulosin component advises caution regarding its co-administration with certain blood thinners, such as warfarin.

This interaction may potentially affect how quickly the body eliminates the Tamsulosin component and is officially noted as an interaction that requires monitoring.

Q: Is Urimax-F ever prescribed for non-prostate issues?

Urimax-F is officially indicated and approved by regulatory bodies exclusively for the treatment of the signs and symptoms associated with an enlarged prostate, also known as Benign Prostatic Hyperplasia (BPH).

Its use as a fixed-dose combination product is limited to this specific indication.

Q: Do different brands of the Urimax-F drug combination work the same way?

Medicines that are approved as generic versions of a brand-name product must meet the same strict standards for quality, strength, purity, and stability.

Regulatory agencies require that generics demonstrate bioequivalence, meaning they are expected to work in the same way as the original brand-name combination.

Q: Does Urimax-F influence driving or operating machinery?

Official guidance addresses the risk of impaired ability to drive or operate machinery due to potential side effects.

Since common side effects include dizziness and lightheadedness, the medicine is associated with documented risks to the ability to drive or operate machinery if those effects are experienced.

Q: Does Urimax-F cause liver problems?

Regulatory information indicates that the Tamsulosin component has been associated with a low rate of temporary changes in liver enzymes.

While the risk of clinically apparent liver injury is noted as very rare, patients with severe hepatic impairment are noted as requiring caution.

Q: What are the most common reasons Urimax-F is discontinued?

Clinical documentation and adverse event profiles indicate that the most common reasons for discontinuing Urimax-F relate to the adverse effects associated with sexual function.

These frequently noted side effects include decreased libido and problems with ejaculation.

Q: What should I do if I think I am experiencing an interaction with Urimax-F?

Official safety information provides clear descriptions for handling serious adverse events.

If signs of a severe reaction, such as swelling of the face or throat (angioedema) or a persistent, painful erection (priapism), these severe reactions are officially listed as requiring immediate medical assistance.

How should Urimax-F be stored and disposed of?

How to Store and Dispose of Urimax-F?

The storage and disposal of this medicine must comply with regulatory requirements to maintain product integrity and ensure safety.

Storage and Handling Requirements

Environment: Store the capsules at room temperature and protect them from light and moisture. The container must be kept tightly closed to protect the contents and should remain in the original container.
Child Safety: The product must be stored out of the sight and reach of children.
Special Handling: Due to risks associated with the finasteride component, pregnant females must not handle crushed or broken capsules. If contact with broken capsules occurs, the exposed area must be washed immediately with soap and water.

Disposal Instructions

Expired/Unused Medicine: Disposal must be done according to local regulations.
Environmental Restriction: Do not dispose of the capsules by flushing them down a toilet, sink, or placing them in household trash. Official guidance recommends using a drug take-back program.

Urimax-F